Overview
I worked within mental health services for a number of years prior to returning to education and completing my undergraduate degree in Human behavioral studies. Following this I completed my MSc with UEMS in Environment and Human Health where I completed a secondary data analysis examining the accumulation and dissipation of Protoporphyrin IX (PpIX) in photodynamic therapy (MAL-PDT), a treatment for non-melanoma skin cancer.
Currently I am working as a Research Associate/ PhD student within the ECEHH on the Smartline project which is a research project looking at how technology can be used to help individual’s live healthier and happier lives. It is a partnership project led by the University of Exeter with Coastline Housing Ltd, Cornwall Council and Volunteer Cornwall.
Qualifications
Dip
FdA
BA(Hons)
MSc
Research
Research interests
I have a wide range of research interests including; human behavior and behavior change, mental health, and respiratory health.
Research projects
- Smartline Project
- PhD: Examining the impact of cold homes, inactivity and the individuals’ microenvironment on respiratory health among adults in social housing in Cornwall
Publications
Key publications | Publications by category | Publications by year
Publications by category
Journal articles
Tyrrell J, Paterson C, Curnow A (2019). Regression Analysis of Protoporphyrin IX Measurements Obtained During Dermatological Photodynamic Therapy.
Cancers (Basel),
11(1).
Abstract:
Regression Analysis of Protoporphyrin IX Measurements Obtained During Dermatological Photodynamic Therapy.
Photodynamic therapy (PDT) is a light activated drug therapy that can be used to treat a number of dermatological cancers and precancers. Improvement of efficacy is required to widen its application. Clinical protoporphyrin IX (PpIX) fluorescence data were obtained using a pre-validated, non-invasive imaging system during routine methyl aminolevulinate (MAL)-PDT treatment of 172 patients with licensed dermatological indications (37.2% actinic keratosis, 27.3% superficial basal cell carcinoma and 35.5% Bowen's disease). Linear and logistic regressions were employed to model any relationships between variables that may have affected PpIX accumulation and/or PpIX photobleaching during irradiation and thus clinical outcome at three months. Patient age was found to be associated with lower PpIX accumulation/photobleaching, however only a reduction in PpIX photobleaching appeared to consistently adversely affect treatment efficacy. Clinical clearance was reduced in lesions located on the limbs, hands and feet with lower PpIX accumulation and subsequent photobleaching adversely affecting the outcome achieved. If air cooling pain relief was employed during light irradiation, PpIX photobleaching was lower and this resulted in an approximate three-fold reduction in the likelihood of achieving clinical clearance. PpIX photobleaching during the first treatment was concluded to be an excellent predictor of clinical outcome across all lesion types.
Abstract.
Author URL.
Full text.
Conferences
Tyrrell J, Paterson C, Curnow A (2019). Insights gained from regression analysis of PpIX fluorescence imaging undertaken during routine dermatological photodynamic therapy.
Abstract:
Insights gained from regression analysis of PpIX fluorescence imaging undertaken during routine dermatological photodynamic therapy
Abstract.
Publications by year
2019
Tyrrell J, Paterson C, Curnow A (2019). Insights gained from regression analysis of PpIX fluorescence imaging undertaken during routine dermatological photodynamic therapy.
Abstract:
Insights gained from regression analysis of PpIX fluorescence imaging undertaken during routine dermatological photodynamic therapy
Abstract.
Tyrrell J, Paterson C, Curnow A (2019). Regression Analysis of Protoporphyrin IX Measurements Obtained During Dermatological Photodynamic Therapy.
Cancers (Basel),
11(1).
Abstract:
Regression Analysis of Protoporphyrin IX Measurements Obtained During Dermatological Photodynamic Therapy.
Photodynamic therapy (PDT) is a light activated drug therapy that can be used to treat a number of dermatological cancers and precancers. Improvement of efficacy is required to widen its application. Clinical protoporphyrin IX (PpIX) fluorescence data were obtained using a pre-validated, non-invasive imaging system during routine methyl aminolevulinate (MAL)-PDT treatment of 172 patients with licensed dermatological indications (37.2% actinic keratosis, 27.3% superficial basal cell carcinoma and 35.5% Bowen's disease). Linear and logistic regressions were employed to model any relationships between variables that may have affected PpIX accumulation and/or PpIX photobleaching during irradiation and thus clinical outcome at three months. Patient age was found to be associated with lower PpIX accumulation/photobleaching, however only a reduction in PpIX photobleaching appeared to consistently adversely affect treatment efficacy. Clinical clearance was reduced in lesions located on the limbs, hands and feet with lower PpIX accumulation and subsequent photobleaching adversely affecting the outcome achieved. If air cooling pain relief was employed during light irradiation, PpIX photobleaching was lower and this resulted in an approximate three-fold reduction in the likelihood of achieving clinical clearance. PpIX photobleaching during the first treatment was concluded to be an excellent predictor of clinical outcome across all lesion types.
Abstract.
Author URL.
Full text.
Cheryl_Paterson Details from cache as at 2020-06-04 05:38:16
Refresh publications
